Chi-Jung Huang, Ph.D.
Have more than 20 years of cancer research experience.
Senior Principal Investigator, Cathay General Hospital
Chief of Clinical Cancer Genetics Laboratory,
Director of Cathay Medical Research Institute.
aaronhuang@cgh.org.tw
Work Experience
| Cathay General Hospital | Senior Principal Investigator/Director | July, 2012 – Present | Human Diseases |
| Cathay General Hospital | Principle Investigator | May, 2003 – Jun, 2012 | Human Diseases |
| Department and Graduate Institute ofBiochemistry, National Defense Medical Center | Adjunct Professor | Feb, 2020 – Present | MolecularBiology, Translational Medicine |
| Department and Graduate Institute ofBiochemistry, National Defense Medical Center | Adjunct Associate Professor | Aug, 2002 – Jan, 2020 | MolecularBiology, Translational Medicine |
| School of Medicine, Fu Jen CatholicUniversity | Adjunct Assistant/Associate Professor | Aug, 2004 – Jul, 2015 | Biochemistry,Biology |
| Kang-Ning Junior College of Medicalcare and Management | Adjunct Lecturer/ Assistant Professor | Aug, 1998 – Jun, 2005 | General Chemistry |
Education
| Graduate Institute of Life Science, NationalDefense Medical Center | Jun, 2002 | Ph.D. |
|---|---|---|
| Department and Graduate Institute ofBiochemistry, National Defense Medical Center | Jun, 1992 | Master |
| School of Medical Technology, National Yang-MingMedical College | Jun, 1990 | Bachelor |
Studies
I mainly use molecular genetics and tumor biology to explore several diseases, especially colorectal cancer (CRC) and inflammatory bowel disease (IBD), covering gene expression analysis of potential molecular markers in stools and understanding of possible relevant gut microbes. Since CRC and IBD are common gastrointestinal diseases, detection of fecal genes or gut microbes will help prevent disease occurrence, detect the disease earlier, reduce the disease incidence, or increase the therapeutic rate of the disease. Recently, animal experiments have been used to further confirm the correlation between intestinal genes and gut microbes, improving the possibility of translational medicine from research to clinical application.